UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 49

Sortiert nach

Characteristics of paroxysmal nocturnal hemoglobinuria patients in Brazil: A retrospective administrative claims database analysis of PNH patients in Brazilian public healthcare system

PloS one, 2023-07, Vol.18 (7), p.e0288708-e0288708

2023

Volltextzugriff (PDF)

Current perspectives on the management of refractory or relapsed classic hodgkin lymphoma in brazil: Balancing efficacy, safety, and tolerability

Oncotarget, 2023-12, Vol.14 (1), p.977-994

2023

Volltextzugriff (PDF)

Difference in FLT3 Mutational Status between Diagnosis and Relapsed/Refractory Acute Myeloid Leukemia: A Meta-Analysis

Blood, 2020-11, Vol.136 (Supplement 1), p.28-29

2020

Volltextzugriff (PDF)

10-year real-world data on acute myeloid leukemia: The paradigm of a public health center in Brazil

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.e19022-e19022

2023

Volltextzugriff (PDF)

Variability in End-of-Life Care and Perception of Palliative Care Among Physicians in the Hematology Unit of a Reference Service in the State of Bahia, Brazil

Blood, 2022-11, Vol.140 (Supplement 1), p.13295-13296

2022

Volltextzugriff (PDF)

Daratumumab (Dara), Cyclophosphamide, Thalidomide and Dexamethasone for Transplant Eligible Newly Diagnosed Multiple Myeloma (TE NDMM) Patients: Response Rate Impacts on PFS

Blood, 2022-11, Vol.140 (Supplement 1), p.7699-7700

2022

Volltextzugriff (PDF)

Retrospective Observational Study of the Long-Term Safety and Efficacy Outcomes of Rituximab Biosimilar: Partial Data of RTXM83-AC-01-11 Subanalysis Study

Blood, 2022-11, Vol.140 (Supplement 1), p.13236-13238

2022

Volltextzugriff (PDF)

Lymphocyte Profiling in Newly Diagnosed Multiple Myeloma: First-Line Treatment with Cyclophosphamide, Thalidomide, Dexamethasone, and Daratumumab

Clinical lymphoma, myeloma and leukemia, 2024-09, Vol.24, p.S246-S246

2024

Volltextzugriff (PDF)

MM-722 Lymphocyte Profiling in Newly Diagnosed Multiple Myeloma: First-Line Treatment with Cyclophosphamide Thalidomide, Dexamethasone, and Daratumumab

Clinical lymphoma, myeloma and leukemia, 2024-09, Vol.24, p.S580-S580

2024

Volltextzugriff (PDF)

10-Year Real-World Data on Acute Myeloid Leukemia: The Paradigm of a Public Health Center in Brazil

Blood, 2020-11, Vol.136 (Supplement 1), p.33-34

2020

Volltextzugriff (PDF)

Evaluation of Hematopoietic Stem Cell Product As a New Site for Minimal Residual Disease By Next Generation Flow in Multiple Myeloma

Blood, 2021-11, Vol.138 (Supplement 1), p.4927-4927

2021

Volltextzugriff (PDF)

Updated safety and efficacy data from an open-label, phase 1/2 study of frontline brentuximab vedotin plus doxorubicin, vinblastine, and dacarbazine (A+AVD) in pediatric patients with advanced-stage classical Hodgkin lymphoma (cHL)

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.10000-10000

2022

Volltextzugriff (PDF)

Isolation of blaNDM-producing Enterobacteriaceae in a public hospital in Salvador, Bahia, Brazil

The Brazilian journal of infectious diseases, 2018-01, Vol.22 (1), p.47-50

2018

Volltextzugriff (PDF)

Preliminary Results of Daratumumab, Cyclophosphamide, Thalidomide and Dexamethasone: A Quadruplet Intensified Treatment for Newly Diagnosed Multiple Myeloma (NDMM) Transplant Eligible (TE) Patients

Blood, 2020-11, Vol.136 (Supplement 1), p.17-18

2020

Volltextzugriff (PDF)

Immune Profiling Evaluation of Newly Diagnose Multiple Myeloma (NDMM) Transplant Eligible (TE) Patients Treated with Daratumumab, Cyclophosphamide, Thalidomide and Dexamethasone. Preliminary Results

Blood, 2020-11, Vol.136 (Supplement 1), p.3-4

2020

Volltextzugriff (PDF)

Liver Injury after Autologous Hematopoietic Stem Cell Transplant: DILI and SOS

Blood, 2018-11, Vol.132 (Supplement 1), p.2161-2161

2018

Volltextzugriff (PDF)

Isolation of [bla.sub.NDM]-producing Enterobacteriaceae in a public hospital in Salvador, Bahia, Brazil

The Brazilian journal of infectious diseases, 2018-01, Vol.22 (1), p.47

2018

Volltextzugriff (PDF)

Nilotinib dose‐optimization in newly diagnosed chronic myeloid leukaemia in chronic phase: final results from ENEST xtnd

British journal of haematology, 2017-10, Vol.179 (2), p.219-228

2017

Volltextzugriff (PDF)

Preliminary results of Daratumumab, cyclophosphamide, thalidomide and dexamethasone- A quadruplet intensified treatment to newly diagnosed multiple myeloma transplant eligible patients

Clinical lymphoma, myeloma and leukemia, 2019-10, Vol.19 (10), p.e145-e146

2019

Volltextzugriff (PDF)

Dose-Optimized Nilotinib (NIL) in Patients (Pts) with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP): Final Results from ENESTxtnd Study

Blood, 2015-12, Vol.126 (23), p.344-344

2015

Volltextzugriff (PDF)

Paraoxonase 1 Activity and Pon 1 Gene Polymorphisms As a Potential Prognostic Biomarker in Sickle Cell Disease

Blood, 2014-12, Vol.124 (21), p.4921-4921

2014

Volltextzugriff (PDF)

Alpha-1 Antitrypsin and SERPINA1 gene Mutation As New Biomarker in Sickle Cell Disease

Blood, 2014-12, Vol.124 (21), p.4918-4918

2014

Volltextzugriff (PDF)

The Interferon Gamma Gene Polymorphism In Acquired Aplastic Anemia and Its Association With HLA

Blood, 2013-11, Vol.122 (21), p.1236-1236

2013

Volltextzugriff (PDF)

1 – 25 von 49

Suche als RSS-Feed

Aktive Filter

ThemaLife Sciences & Biomedicine

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(39)
Mit Volltextzugriff
(49)

Publikationsform

Artikel
(48)
Berichte
(1)

Sprache

Englisch
(46)
Portugiesisch
(6)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 7 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Characteristics of paroxysmal nocturnal hemoglobinuria patients in Brazil: A retrospective administrative claims database analysis of PNH patients in Brazilian public healthcare system

Current perspectives on the management of refractory or relapsed classic hodgkin lymphoma in brazil: Balancing efficacy, safety, and tolerability

Difference in FLT3 Mutational Status between Diagnosis and Relapsed/Refractory Acute Myeloid Leukemia: A Meta-Analysis

10-year real-world data on acute myeloid leukemia: The paradigm of a public health center in Brazil

Variability in End-of-Life Care and Perception of Palliative Care Among Physicians in the Hematology Unit of a Reference Service in the State of Bahia, Brazil

Daratumumab (Dara), Cyclophosphamide, Thalidomide and Dexamethasone for Transplant Eligible Newly Diagnosed Multiple Myeloma (TE NDMM) Patients: Response Rate Impacts on PFS

Retrospective Observational Study of the Long-Term Safety and Efficacy Outcomes of Rituximab Biosimilar: Partial Data of RTXM83-AC-01-11 Subanalysis Study

Lymphocyte Profiling in Newly Diagnosed Multiple Myeloma: First-Line Treatment with Cyclophosphamide, Thalidomide, Dexamethasone, and Daratumumab

MM-722 Lymphocyte Profiling in Newly Diagnosed Multiple Myeloma: First-Line Treatment with Cyclophosphamide Thalidomide, Dexamethasone, and Daratumumab

10-Year Real-World Data on Acute Myeloid Leukemia: The Paradigm of a Public Health Center in Brazil

Evaluation of Hematopoietic Stem Cell Product As a New Site for Minimal Residual Disease By Next Generation Flow in Multiple Myeloma

Updated safety and efficacy data from an open-label, phase 1/2 study of frontline brentuximab vedotin plus doxorubicin, vinblastine, and dacarbazine (A+AVD) in pediatric patients with advanced-stage classical Hodgkin lymphoma (cHL)

Isolation of blaNDM-producing Enterobacteriaceae in a public hospital in Salvador, Bahia, Brazil

Progression Free Survival (PFS) Analysis of Daratumumab (Dara), Cyclophosphamide, Thalidomide and Dexamethasone: A Quadruplet Intensified Treatment for Transplant Eligible Newly Diagnosed Multiple Myeloma (TE NDMM) Patients

Preliminary Results of Daratumumab, Cyclophosphamide, Thalidomide and Dexamethasone: A Quadruplet Intensified Treatment for Newly Diagnosed Multiple Myeloma (NDMM) Transplant Eligible (TE) Patients

Immune Profiling Evaluation of Newly Diagnose Multiple Myeloma (NDMM) Transplant Eligible (TE) Patients Treated with Daratumumab, Cyclophosphamide, Thalidomide and Dexamethasone. Preliminary Results

First Description of Upfront Target Therapy Treating AML and Bcll Presented Simultaneously As First Line

Liver Injury after Autologous Hematopoietic Stem Cell Transplant: DILI and SOS

Isolation of [bla.sub.NDM]-producing Enterobacteriaceae in a public hospital in Salvador, Bahia, Brazil

Nilotinib dose‐optimization in newly diagnosed chronic myeloid leukaemia in chronic phase: final results from ENEST xtnd

Preliminary results of Daratumumab, cyclophosphamide, thalidomide and dexamethasone- A quadruplet intensified treatment to newly diagnosed multiple myeloma transplant eligible patients

Dose-Optimized Nilotinib (NIL) in Patients (Pts) with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP): Final Results from ENESTxtnd Study

Paraoxonase 1 Activity and Pon 1 Gene Polymorphisms As a Potential Prognostic Biomarker in Sickle Cell Disease

Alpha-1 Antitrypsin and SERPINA1 gene Mutation As New Biomarker in Sickle Cell Disease

The Interferon Gamma Gene Polymorphism In Acquired Aplastic Anemia and Its Association With HLA

Aktive Filter

Suchergebnisse filtern